Candel Therapeutics heads into its May 21 earnings print with a heavyweight short base, a stock up 72% over the past month, and a conflicted Street watching whether clinical momentum can justify a rally that bears clearly don't believe in.
Short sellers have been steadily adding into the price strength. Short interest as a percentage of free float has climbed to 24%, up from about 22.5% a month ago, with week-on-week growth of just over 4%. That is a crowded short for a small-cap biotech — roughly one in four freely tradeable shares is currently on loan. The ORTEX short score of 80, placing CADL in the 4th percentile of its universe on that factor rank, underlines just how heavily skewed bearish positioning has become. The bears have been adding consistently, not panicking — this is a deliberate rebuild, not a squeeze hangover.
The borrow market itself is less alarming than the headline SI figure suggests. Cost to borrow has actually eased over the past month, dropping about 15% to sit around 2.7% APR — not the kind of rate that signals a desperate scramble for shares. Availability has also loosened from its tightest recent levels, with the share of the borrow pool still available hovering well above zero, after utilization peaked near 100% earlier in the year. On the options side, the put/call ratio nudged up to 0.33 on Friday — slightly above its 20-day average of 0.29, around one standard deviation elevated, but nowhere near its 52-week high of 0.79. Options traders are mildly more defensive than usual, but this is not a panic hedge. The positioning picture, taken together, reads as a large but comfortable short base, not an imminent squeeze setup.
The Street is broadly constructive, though the most recent analyst activity is worth noting. Cantor Fitzgerald initiated coverage at Overweight in late April — a fresh vote of confidence just weeks before earnings. Citigroup has been the most active voice, raising its target to $26 from $22 in March after briefly trimming it on the day of the prior print. Canaccord holds at $25. Those numbers sit well above the current $8.77 price, a gap that reflects either a mismatch in expectations or the Street's conviction in the pipeline runway. The bull case centres on CADL's viral immunotherapy platforms — CAN-2409 and CAN-3110 — and their ability to convert "cold" tumours into immunologically active targets. The bear case is more prosaic: FDA approval uncertainty, execution risk on manufacturing scale-up, and cash burn from a company with no revenue and a deeply negative enterprise value. The price-to-book multiple has risen about 20% over the past month as the stock rallied, now near 1.2x — a sign the market is pricing in pipeline optionality, not fundamentals.
One institutional thread worth flagging: Paul Manning, the Independent Chairman, bought nearly 3 million dollars' worth of shares in late February at $5.45. That followed a $5 million purchase he made in June 2025 at $4.67, alongside a cluster of C-suite buys — CEO Paul Tak, acting CFO Charles Schoch, CTO Seshu Tyagarajan, and the CSO all participated in that June round. The chairman now holds over 6% of the company. That is a material, multi-quarter insider accumulation that preceded a 60%-plus re-rating of the stock. FMR (Fidelity) holds another 11% and added 835,000 shares in Q1. Vanguard added 652,000. The institutional base is building even as the short interest builds with it — an unusual tension.
Prior earnings reactions have been mixed but skewed negative. The March 2026 print saw the stock fall over 8% on the day. The November 2025 event produced a modest initial gain but a slight loss over five days. May 14 saw a 1.9% decline following the most recent announcement. The pattern suggests the stock tends to give back ground around results. Next week's print — May 21 — therefore arrives with the stock trading at levels almost double where insiders were buying just months ago, a short base that has rebuilt into the rally, and a Street whose targets imply far more upside but whose recent reaction history shows restraint in rewarding news. Whether the pipeline data or cash runway guidance justifies the current price is the central question the print will need to answer.
See the live data behind this article on ORTEX.
Open CADL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
